目的：分析血清可溶性细胞间黏附分子1(sICAM-1)、可溶性血管细胞黏附分子1(sVCAM-1)水平与甲状腺相关眼病(TAO)病情严重程度的相关性。

方法：选取我院2016-08/2018-03收治的TAO患者120例，依据临床活动性评分(CAS)标准(活动期组、非活动期组)和病情严重程度(轻度组、中重度组、极重度组)分组，并取同期健康体检者90例纳入对照组，比较各组受检者临床基本资料及血清sICAM-1、sVCAM-1水平，并分析血清sICAM-1、sVCAM-1水平与TAO病情严重程度的相关性。

结果：不同临床活性分期组与对照组受检者，不同病情严重程度组与对照组受检者临床基本资料比较，差异均无统计学意义(P>0.05)。活动期组患者血清sICAM-1、sVCAM-1水平均明显高于非活动期组和对照组受检者，差异均有统计学意义(P<0.01)。不同病情严重程度组活动期患者血清sICAM-1、sVCAM-1水平明显高于非活动期和对照组，差异均有统计学意义(P<0.01)。不同病情严重程度组非活动期患者血清sICAM-1、sVCAM-1水平无明显差异，不同病情严重程度组活动期患者血清sICAM-1、sVCAM-1水平随病情加重逐渐升高。非活动期患者血清sICAM-1、sVCAM-1水平与其病情严重程度无明显相关性(r=0.102、0.095，P=0.135、0.167)； 活动期患者血清sICAM-1、sVCAM-1水平与其病情严重程度呈正相关(r=0.695、0.824，P=0.005、0.002)。

结论：非活动期患者血清sICAM-1、sVCAM-1水平不会随病情加重而升高，活动期患者血清sICAM-1、sVCAM-1水平随病情加重明显升高，可用于TAO的临床诊断、分期分级及预后监测。

METHODS: A total of 120 patients with TAO admitted to the hospital from August 2016 to March 2018 were selected and included in the study. According to the clinical activity score(CAS), the patients were divided into active stage group and inactive stage group. According to the severity, they were divided into mild group, moderate group and severe group. There were 90 healthy persons were selected as the control group at the same time. The general data, serum sICAM-1 and sVCAM-1 levels were compared among groups and the correlation of sICAM-1 and sVCAM-1 levels with the severity of TAO was analyzed.

RESULTS: There were no significant differences in the clinical basic data of patients in between the different clinical active stage groups and the control group, and between the different severity groups and the control group(P>0.05). The levels of serum sICAM-1 and sVCAM-1 in the active stage group were significantly higher than those in the inactive stage group and the control group(P<0.01). The levels of serum sICAM-1 and sVCAM-1 in active stage patients of different severity groups were significantly higher than those in inactive stage patients and of control groups(P<0.01). There were no significant differences in levels of serum sICAM-1 and sVCAM-1 in inactive stage patients of different severity groups. The levels of serum sICAM-1 and sVCAM-1 in active stage patients of different severity groups increased gradually with the severity of the disease. There was no significant correlation between levels of serum sICAM-1 and sVCAM-1 in inactive stage patients and the severity of disease(r=0.102, 0.095, P=0.135, 0.167). Levels of serum sICAM-1 and sVCAM-1 in active stage patients were positively correlated to severity of disease(r=0.695, 0.824, P=0.005, 0.002).

CONCLUSION: The levels of serum sICAM-1 and sVCAM-1 in inactive patients will not increase with the severity of the disease. However, the levels in patients with active disease will increase with the severity of the disease, which can be used for clinical diagnosis and staging of TAO and monitoring of the prognosis.